Mar 16, 2017 4:48 pm EDT CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23
Jan 05, 2017 8:00 am EST CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate
Jan 03, 2017 4:01 pm EST CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States
Dec 08, 2016 8:00 am EST CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors
Dec 07, 2016 8:00 am EST CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis